Regeneron Pharmaceuticals Inc. (REGN)
REGN trades on Nasdaq in Health Care, Biotechnology: Pharmaceutical Preparations. Numbers below come from the Nasdaq screener and SEC filings, each with its source.
Price · October 14, 2026
$753.12
-1.27% on the day
Market cap
$77.5B
Large cap
Revenue · 2025
$14.3B
+1.0% on 2024
Net income · 2025
$4.5B
31.4% net margin
Price, change, market cap, sector and industry: Nasdaq stock screener, as of October 14, 2026. Revenue: SEC XBRL frames, calendar 2025.
Profile
| Field | Value |
|---|---|
| Ticker | REGN on Nasdaq |
| Sector | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations |
| Country | United States |
| IPO year | 1991 |
| SEC CIK | 0000872589 |
| SEC industry code | Pharmaceutical Preparations |
| Incorporated in | NY |
Financials · 2025
| Line | Value |
|---|---|
| Revenue | $14.3B |
| Net income | $4.5B |
| Operating income | $3.6B |
| Net margin | 31.4% |
| Operating margin | 24.9% |
| Revenue growth | +1.0% |
| Cash | $3.1B |
| Total assets | $40.6B |
| P/E (computed) | 17.2× |
| P/S (computed) | 5.4× |
Key SEC documents
| Document | Form | Filed |
|---|---|---|
| Latest prospectus or offering document | S-3ASR | 2024-10-31 |
| Latest annual report | 10-K | 2026-02-04 |
| Latest quarterly / interim | 10-Q | 2026-07-30 |
| Latest current report FORM 8-K | 8-K | 2026-10-06 |
| Latest proxy DEFINITIVE ADDITIONAL PROXY SOLICITING MATERIALS | DEFA14A | 2026-04-24 |
Source: SEC EDGAR submissions feed, 1,001 recent filings. All filings on EDGAR.
Price moves
| Window | Return |
|---|---|
| 1 week | +5.3% |
| 1 month | +0.9% |
| 3 months | +15.1% |
| Year to date | +1.2% |
| 1 year | +40.1% |
| From 52-week high | -8.3% |
Source: Yahoo Finance daily closes, last bar 2026-10-14. Computed by Sophia Capital from daily closes; cap, sector and tier from the Nasdaq screener.
Peers in Biotechnology: Pharmaceutical Preparations
| Ticker | Company | Price | Day | Market cap |
|---|---|---|---|---|
| GSK | GSK plc | $46.27 | -1.39% | $93.6B |
| SNY | Sanofi ADS | $39.12 | -1.56% | $95.4B |
| TAK | Takeda Pharmaceutical Company Limited | $18.52 | -0.86% | $58.5B |
| BMY | Bristol-Myers Squibb Company | $56.67 | -1.58% | $115.8B |
| VRTX | Vertex Pharmaceuticals Incorporated | $485.22 | -4.30% | $123.0B |
| TEVA | Teva Pharmaceutical Industries Limited | $41.25 | +0.19% | $48.1B |
| ONC | BeOne Medicines Ltd. | $349.08 | -0.38% | $39.7B |
| PFE | Pfizer Inc. | $28.37 | -0.11% | $161.7B |
The full dossier has every filing, three years of financials, private raises and the people who signed them.
Open the full dossier